Emerging MAPK-Targeted Therapies Beyond BRAF V600 Mutation
New therapeutic strategies targeting the MAPK pathway beyond the BRAF V600 mutation are emerging, as reported in the Annals of Translational Medicine. These approaches aim to improve treatment outcomes by addressing additional molecular targets within the MAPK signaling cascade, expanding options for patients with cancers driven by this pathway.
Annals of Translational Medicine·


